Clinical trials
Uterine Cervical Neoplasms trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 3 |
| Recruiting | 3 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 1 |
| Bayer | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Hoffmann-La Roche | 1 |
| Iovance Biotherapeutics, Inc. | 1 |
| Medicenna Therapeutics, Inc. | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Oncology Institute of Southern Switzerland | 1 |
| Prof. Patrick Petignat | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Cervical Neoplasms | 13 |
| Esophageal Neoplasms | 4 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
| Stomach Neoplasms | 4 |
| Urinary Bladder Neoplasms | 4 |
| Carcinoma, Ovarian Epithelial | 3 |
| Endometrial Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
Trials
Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.